Почетна › Urotelni (prelaznoćelijski) karcinom › Вашингтон
Kliničke studije za Urotelni (prelaznoćelijski) karcinom u državi Вашингтон
13 studija za Urotelni (prelaznoćelijski) karcinom traži učesnike na lokacijama u državi Вашингтон.
Gradovi u državi Вашингтон
Zvanični tekst studije (na engleskom)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Kadlec Clinic Hematology and Oncology, Kennewick
- Valley Medical Center, Renton
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03866382A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Swedish Cancer Institute Medical Oncology, Edmonds
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06270706A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- FHCC Overlake, Bellevue
- FHCC at EvergreenHealth, Kirkland
- Fred Hutchinson Cancer Center, Seattle
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06524544A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Wenatchee Valley Hospital and Clinics, Wenatchee
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06330064Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Eye Associates Northwest - Edmonds Clinic, Edmonds
- Eye Associates Northwest - Kirkland Clinic, Kirkland
- Eye Associates Northwest - Ballard Clinic and Surgery Center, Seattle
- и још 6
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Swedish Cancer Institute, Seattle
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT07277413Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Northwest Medical Specialties, Tacoma
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2026. · NCT06047379A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
- Research Site, Spokane
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 11. 9. 2026. · NCT07815665A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 10. 9. 2026. · NCT06040762A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- Harborview Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center, Seattle
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 22. 7. 2026. · NCT04879329An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Seattle
- Research Site, Tacoma
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 22. 7. 2026. · NCT07720284SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774A Study of NX-1607 in Adults With Advanced Malignancies
- Fred Hutchinson Cancer Center, Seattle
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 9. 2025. · NCT05107674Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.